University of Liverpool partners with myNEO Therapeutics for personalised therapeutic cancer vaccine trial

The University of Liverpool and myNEO Therapeutics have announced a strategic partnership to support a Phase 1 clinical trial aimed at developing a personalised therapeutic cancer vaccine for patients with Non-Small Cell Lung Cancer (NSCLC).

The trial, which will recruit 10 NSCLC patients, represents a significant step forward in the development of individualised cancer immunotherapies. myNEO Therapeutics will provide advanced neoantigen prediction capabilities to identify patient-specific targets, enabling the creation of a personalised vaccine tailored to each patient’s unique tumour profile.

Cedric Bogaert, CEO of myNEO Therapeutics said: "Our collaboration with the University of Liverpool exemplifies our commitment to pioneering personalised medicine in oncology. Using our proprietary ImmunoEngine technology, we aim to identify and prioritise neoantigens that are most likely to elicit a robust immune response, ultimately enhancing the effectiveness of the vaccine. It's humbling to see how our years of dedicated technology development are resulting in a broad clinical pipeline of both in-house and external developments, tackling numerous cancer indications in parallel."

myNEO’s ImmunoEngine technology combines state-of-the-art AI algorithms, genomics, and bioinformatics to analyse tumour-specific mutations and predict the most promising neoantigens for targeting. This innovative approach is designed to activate the patient’s immune system against cancer cells while minimizing the risk of off-target effects.

The University of Liverpool’s planned trial marks a crucial development in the quest for new, personalised therapeutic options for NSCLC, the most common form of lung cancer. By focusing on individual patient profiles, this trial seeks to harness the potential of personalised vaccines to deliver more effective and tailored treatments for those affected by this challenging disease.

Christian Ottensmeier, Professor of Immuno-Oncology at the University of Liverpool and Director of Clinical Research at The Clatterbridge Centre said: "We are excited to collaborate with myNEO Therapeutics on this personalised vaccine trial. Their expertise in neoantigen prediction is vital to the development of a therapeutic vaccine that could significantly impact patient outcomes."

This partnership builds on myNEO Therapeutics’ ongoing efforts to advance the field of cancer immunotherapy through innovative and personalised solutions. The company remains dedicated to leveraging its technology platform to support clinical trials and partnerships that drive forward the development of next-generation cancer treatments.